The market has soared to begin 2013 with many biotech companies leading the way. That should be no surprise given the massive swings that companies can make in just a week's time. Unfortunately, some biotech stocks have also lagged the returns of the broader market. In the following video, Fool contributor Maxx Chatsko reviews the five coldest biotech stocks through the first five months of the year and tells investors if things are about to get better any time soon. Not all laggards are created equal.
Resurgence, or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy by clicking here now.
The article 5 Worst Biotechs of 2013 originally appeared on Fool.com.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.